Extranodal NK-T-cell lymphoma differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 27: | Line 27: | ||
=== Differentiating extranodal NK T-cell from other hematologic malignancies by immunophenotype and EBV infection: === | === Differentiating extranodal NK T-cell from other hematologic malignancies by immunophenotype and EBV infection: === | ||
Extranodal NK T-cell lymphoma express [[CD56]] on its surface accompanied with [[EBV]] infection. | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width:600px" | {| style="border: 0px; font-size: 90%; margin: 3px; width:600px" | ||
| valign="top" | | | valign="top" | | ||
|+ | |+ | ||
'''Malignancies based on immunophenotype and EBV infection''' | '''Malignancies based on immunophenotype and EBV infection''' | ||
!style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF|Disease}} | ! style="background: #4479BA; width: 250px;" |{{fontcolor|#FFF|Disease}} | ||
!style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF|immunophenotype}} | ! style="background: #4479BA; width: 250px;" |{{fontcolor|#FFF|immunophenotype}} | ||
!style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|EBV}} | ! style="background: #4479BA; width: 100px;" |{{fontcolor|#FFF|EBV}} | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[NK cell leukemia]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[NK cell leukemia]] | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD16+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD16]]+ | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | + | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Lymphomatoid granulomatosis]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Lymphomatoid granulomatosis]] | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD20+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD20]]+ | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | + | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Diffuse large B cell lymphoma|EBV-positive diffuse large B cell lymphoma, NOS]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Diffuse large B cell lymphoma|EBV-positive diffuse large B cell lymphoma, NOS]] | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD20+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD20]]+ [[CD76]]+ | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | + | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Peripheral T cell lymphoma|Peripheral T cell lymphoma, unspecified]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Peripheral T cell lymphoma|Peripheral T cell lymphoma, unspecified]] | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD3+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD3 (immunology)|CD3]]+ [[CD56]]- | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |- | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | - | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Anaplastic large cell lymphoma, ALK positive|Anaplastic large cell lymphoma]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Anaplastic large cell lymphoma, ALK positive|Anaplastic large cell lymphoma]] | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD30+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD30]]+ | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |- | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | - | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Hepatosplenic T cell lymphoma]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Hepatosplenic T cell lymphoma]] | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD2+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD2]]+ [[CD70|CD7]]+ [[CD3 (immunology)|CD3]]+ | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |- | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | - | ||
|} | |} | ||
Revision as of 16:03, 26 August 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2] Sowminya Arikapudi, M.B,B.S. [3]
Overview
Extranodal NK-T-cell lymphoma must be differentiated from other diseases such as NK cell lukemia, lymphomatoid granulomatosis, EBV-positive diffuse large B cell lymphoma, NOS, anaplastic large cell lymphoma, non specific inflammatory process, enteropathy associated T cell lymphoma, peripheral T cell lymphoma, hepatosplenic T cell lymphoma
Extranodal NK/T-cell lymphoma, nasal type must be diffrentiated from Wegner's granulomatosis, Polymorphic reticulosis, and Midline malignant lymphoma
Differential Diagnosis
Extranodal NK t-cell must be differentiated with other NK and T cell hematologic malignancies and EBV-associated T cell or NK cell lymphoprolifrative disorders.[1]
Extranodal NK-T-cell lymphoma must be differentiated from other diseases such as:[2]
- NK cell lukemia[3]
- Lymphomatoid granulomatosis
- EBV-positive diffuse large B cell lymphoma, NOS
- Anaplastic large cell lymphoma
- Non specific inflammatory process
- Enteropathy associated T cell lymphoma
- Peripheral T cell lymphoma
- Hepatosplenic T cell lymphoma
Extranodal NK-T cell lymphoma, nasal type shows aggresive lethal midline granuloma macroscopicaly so it must be differentiated from diseases such as:[4]
- Wegner's granulomatosis
- Polymorphic reticulosis
- Midline malignant lymphoma
Differentiating extranodal NK T-cell from other hematologic malignancies by immunophenotype and EBV infection:
Extranodal NK T-cell lymphoma express CD56 on its surface accompanied with EBV infection.
| Disease | immunophenotype | EBV |
|---|---|---|
| NK cell leukemia | CD16+ | + |
| Lymphomatoid granulomatosis | CD20+ | + |
| EBV-positive diffuse large B cell lymphoma, NOS | CD20+ CD76+ | + |
| Peripheral T cell lymphoma, unspecified | CD3+ CD56- | - |
| Anaplastic large cell lymphoma | CD30+ | - |
| Hepatosplenic T cell lymphoma | CD2+ CD7+ CD3+ | - |
References
- ↑ Karube, Kennosuke; Aoki, Ryosuke; Nomura, Yuko; Yamamoto, Kohei; Shimizu, Kay; Yoshida, Shirou; Komatani, Hideki; Sugita, Yasuo; Ohshima, Koichi (2008). "Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: Analysis of 490 cases". Pathology International. 58 (2): 89–97. doi:10.1111/j.1440-1827.2007.02195.x. ISSN 1320-5463.
- ↑ Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type. Hindawi Publishing Corporation. http://www.hindawi.com/journals/ah/2010/627401/. Accessed on February 19, 2016
- ↑ Kassel SH, Echevarria RA, Guzzo FP (1969). "Midline malignant reticulosis (so-called lethal midline granuloma)". Cancer. 23 (4): 920–35. doi:10.1002/1097-0142(196904)23:4<920::aid-cncr2820230430>3.0.co;2-m. PMID 5818523.
- ↑ Kassel SH, Echevarria RA, Guzzo FP (1969). "Midline malignant reticulosis (so-called lethal midline granuloma)". Cancer. 23 (4): 920–35. doi:10.1002/1097-0142(196904)23:4<920::aid-cncr2820230430>3.0.co;2-m. PMID 5818523.